home / stock / tryp:cc / tryp:cc news

TRYP:CC News and Press, Tryp Therapeutics Inc. From 04/28/22

Stock Information
Company Name: Tryp Therapeutics Inc.
Stock Symbol: TRYP:CC
Market: CNQC
Website: tryptherapeutics.com
Menu
TRYP:CC TRYP:CC Quote TRYP:CC Short TRYP:CC News TRYP:CC Articles TRYP:CC Message Board
Get TRYP:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TRYP:CC - TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL

TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL Canada NewsWire Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder SAN DIEGO , ...
TRYP:CC - TRYP THERAPEUTICS INC. Announces Amendment to Terms of Private Placement and Closing of $3,000,000 Second Tranche

(TheNewswire) SAN DIEGO, CALIFORNIA – TheNewswire - April 22, 2022 – Tryp Therapeutics (CSE:TRYP) (OTC:TRYPF) (“ Tryp ” or the “ Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases ...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Initiates Enrollment for Study to Evaluate TRP-8802 to Treat Binge Eating Disorder

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the first patient enrolled to evaluate its clinical candidate, TRP-8802, in a clinical trial. The study will be con...

TRYP:CC - Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida Canada NewsWire Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO...
Previous 10 Next 10